Loading
A phase 1/2 trial of Gotistobart, Pembrolizumab, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by OncoC4, Inc., active and no longer recruiting.
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC is a phase 1/2 interventional study registered as NCT04140526 by OncoC4, Inc., with 733 participants planned, started 2020-09-16 and due to reach its primary completion in 2026-12-31. Interventions recorded: ONC-392, Pembrolizumab, Docetaxel. Conditions listed: Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares OncoC4, Gotistobart, Pembrolizumab, Immune checkpoint inhibitors.
Shares OncoC4, Gotistobart, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Melanoma, Colorectal cancer.
Shares OncoC4, Gotistobart.
Shares Docetaxel, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Colorectal cancer, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/